SEC Info - Unilife Corp - ‘10-Q’ for 9/30/13

Unilife Corp – ‘10-Q’ for 9/30/13 – ‘R8’

On: Tuesday, 11/12/13, at 5:16pm ET · For: 9/30/13 · Accession #: 1193125-13-438524 · File #: 1-34540

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/12/13 Unilife Corp 10-Q 9/30/13 52:2.7M Donnelley … Solutions/FA

Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 208K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 22K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 22K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 18K 51: R1 Document and Entity Information HTML 39K 36: R2 Consolidated Balance Sheets HTML 111K 33: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K 14: R4 Consolidated Statements of Operations and HTML 65K Comprehensive Loss 35: R5 Consolidated Statement of Stockholders' Equity HTML 54K 23: R6 Consolidated Statements of Cash Flows HTML 92K 45: R7 Description of Business and Unaudited Financial HTML 22K Statements 24: R8 Liquidity HTML 24K 26: R9 Summary of Significant Accounting Policies HTML 30K 15: R10 Equity Transactions and Share-Based Compensation HTML 56K 25: R11 Property, Plant and Equipment and HTML 29K Construction-in-Progress 44: R12 Goodwill and Intangible Assets HTML 27K 41: R13 Long-Term Debt HTML 36K 34: R14 Net Loss Per Share HTML 30K 48: R15 Contingencies HTML 29K 43: R16 Business Alliances HTML 22K 12: R17 Summary of Significant Accounting Policies HTML 51K (Policies) 17: R18 Equity Transactions and Share-Based Compensation HTML 52K (Tables) 47: R19 Property, Plant and Equipment and HTML 28K Construction-in-Progress (Tables) 50: R20 Goodwill and Intangible Assets (Tables) HTML 22K 52: R21 Long-Term Debt (Tables) HTML 30K 49: R22 Net Loss Per Share (Tables) HTML 26K 38: R23 Liquidity - Additional Information (Detail) HTML 27K 16: R24 Equity Transactions and Share-Based Compensation - HTML 45K Additional Information (Detail) 22: R25 Equity Transactions and Share-Based Compensation - HTML 50K Schedule of Stock Options Activity by Employees and Directors (Detail) 19: R26 Equity Transactions and Share-Based Compensation - HTML 50K Schedule of Stock Options Activity by Other than Employees and Directors (Detail) 18: R27 Equity Transactions and Share-Based Compensation - HTML 31K Fair Value of Options Granted (Detail) 27: R28 Equity Transactions and Share-Based Compensation - HTML 40K Summary of Activity Related to Restricted Stock Awards (Detail) 37: R29 Property, Plant and Equipment and HTML 45K Construction-in-Progress - Components of Property, Plant and Equipment and Construction-in-Progress (Detail) 42: R30 Goodwill and Intangible Assets - Changes in HTML 23K Carrying Amount of Goodwill (Detail) 21: R31 Goodwill and Intangible Assets - Additional HTML 24K Information (Detail) 28: R32 Long-Term Debt - Components of Long-Term Debt HTML 32K (Detail) 46: R33 Long-Term Debt - Components of Long-Term Debt HTML 29K (Parenthetical) (Detail) 20: R34 Long-Term Debt - Additional Information (Detail) HTML 66K 39: R35 Net Loss Per Share - Net Loss Per Share (Detail) HTML 36K 40: R36 Net Loss Per Share - Additional Information HTML 26K (Detail) 29: R37 Business Alliances - Additional Information HTML 29K (Detail) 32: XML IDEA XML File -- Filing Summary XML 75K 13: EXCEL IDEA Workbook of Financial Reports XLSX 84K 31: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 281K 6: EX-101.INS XBRL Instance -- unis-20130930 XML 494K 8: EX-101.CAL XBRL Calculations -- unis-20130930_cal XML 129K 9: EX-101.DEF XBRL Definitions -- unis-20130930_def XML 271K 10: EX-101.LAB XBRL Labels -- unis-20130930_lab XML 697K 11: EX-101.PRE XBRL Presentations -- unis-20130930_pre XML 493K 7: EX-101.SCH XBRL Schema -- unis-20130930 XSD 99K 30: ZIP XBRL Zipped Folder -- 0001193125-13-438524-xbrl Zip 79K

Liquidity

3 Months Ended

Sep. 30, 2013

Text Block [Abstract]

Liquidity

2. Liquidity

The Company has incurred recurring losses from operations during the year ended June 30, 2013, and the three months ended September 30, 2013, and anticipates incurring additional losses until such time that it can generate sufficient revenue from the sale, customization, or exclusive use and licensing of its proprietary range of injectable drug delivery systems to pharmaceutical and biotechnology customers. Management has taken such steps delineated below to address its cash requirements.

The Company needs additional funding to support its operations and capital expenditure requirements. The Company continues to have discussions with current and prospective customers for many active programs in its commercial pipeline and expects to progressively execute agreements featuring a combination of revenue streams including exclusivity fees, device customization programs and supply contracts that are expected to generate cash payments to the Company during calendar 2014. Given the substantial size, complexity and long-term duration of many of these prospective agreements, some can take a significant time to negotiate and finalize. The Company is consciously managing its cash position to minimize raising additional equity capital and thereby minimize dilution to existing stockholders.

The Company continues to evaluate debt funding programs available to the Company as part of its overall financing strategy. Combined with the ancipated revenue to be generated from new and existing customer agreements or through other transactions, the Company expects to have sufficient near term liquidity. However, there can be no assurance that such additional funding, or sales transactions, will close as expected or be available when needed. These various factors continue to raise substantial doubt about the Company’s ability to continue as a going concern.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

In October 2012, the Company entered into a Controlled Equity Offering Sales Agreement, (the “Sales Agreement”) pursuant to which the Company may, from time to time, issue and sell shares of common stock having an aggregate offering price of up to $45.0 million. During the three months ended September 30, 2013, the Company issued 3,512,153 shares of common stock and raised approximately $10.7 million under the Sales Agreement. The Company is not obligated to make any additional sales of shares under the Sales Agreement. As of September 30, 2013, there was approximately $19.2 million available under the Sales Agreement.

This ‘10-Q’ Filing

Date

Other Filings

Filed on:

11/12/13

8-K

For Period end:

9/30/13

6/30/13

10-K, 4

List all Filings

Unilife Corp – ‘10-Q’ for 9/30/13 – ‘R8’

On: Tuesday, 11/12/13, at 5:16pm ET · For: 9/30/13 · Accession #: 1193125-13-438524 · File #: 1-34540

Previous ‘10-Q’: ‘10-Q’ on 5/10/13 for 3/31/13 · Next: ‘10-Q’ on 2/10/14 for 12/31/13 · Latest: ‘10-Q’ on 2/9/17 for 12/31/16

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘R8’ — Liquidity

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Unilife Corp – ‘10-Q’ for 9/30/13 – ‘R8’

On: Tuesday, 11/12/13, at 5:16pm ET · For: 9/30/13 · Accession #: 1193125-13-438524 · File #: 1-34540

Previous ‘10-Q’: ‘10-Q’ on 5/10/13 for 3/31/13 · Next: ‘10-Q’ on 2/10/14 for 12/31/13 · Latest: ‘10-Q’ on 2/9/17 for 12/31/16

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘R8’ — Liquidity

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents